EyePoint Pharmaceuticals (EYPT) Income from Continuing Operations: 2010-2018
Historic Income from Continuing Operations for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Sep 2018 value amounting to -$14.4 million.
- EyePoint Pharmaceuticals' Income from Continuing Operations fell 139.24% to -$14.4 million in Q3 2018 from the same period last year, while for Sep 2018 it was -$34.6 million, marking a year-over-year decrease of 99.88%. This contributed to the annual value of -$53.2 million for FY2018, which is 187.64% down from last year.
- EyePoint Pharmaceuticals' Income from Continuing Operations amounted to -$14.4 million in Q3 2018, which was down 46.89% from -$9.8 million recorded in Q2 2018.
- Over the past 5 years, EyePoint Pharmaceuticals' Income from Continuing Operations peaked at $20.6 million during Q3 2014, and registered a low of -$14.4 million during Q3 2018.
- Moreover, its 3-year median value for Income from Continuing Operations was -$6.0 million (2017), whereas its average is -$6.4 million.
- Per our database at Business Quant, EyePoint Pharmaceuticals' Income from Continuing Operations skyrocketed by 657.80% in 2014 and then tumbled by 8,568.66% in 2017.
- Quarterly analysis of 5 years shows EyePoint Pharmaceuticals' Income from Continuing Operations stood at -$4.1 million in 2014, then dropped by 27.26% to -$5.2 million in 2015, then skyrocketed by 98.71% to -$67,000 in 2016, then tumbled by 8,568.66% to -$5.8 million in 2017, then crashed by 139.24% to -$14.4 million in 2018.
- Its Income from Continuing Operations stands at -$14.4 million for Q3 2018, versus -$9.8 million for Q2 2018 and -$4.7 million for Q1 2018.